Korro Bio holder buys shares, pre-funded warrants
SANDELL SCOTT D reported open-market purchase transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SANDELL SCOTT D reported open-market purchase transactions in this Form 4 filing.
Korro Bio, Inc. insider entities linked to Scott D. Sandell indirectly acquired 242,945 Pre-Funded Warrants and 207,100 shares of Common Stock on March 10, 2026, pursuant to a Subscription Agreement dated March 9, 2026.
The Pre-Funded Warrants carry a $0.001 exercise price and are exercisable at any time, subject to a 9.99% ownership cap that can be adjusted up to 19.99% with 61 days’ notice.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Pre-Funded Warrants | 242,945 | $11.109 | $2.70M |
| Purchase | Common Stock | 207,100 | $11.11 | $2.30M |
Footnotes (3)
- F1. Acquired from the Issuer on March 10, 2026 pursuant to a Subscription Agreement dated March 9, 2026.
- F2. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.
- F3. The Pre-Funded Warrants are exercisable at any time after their issuance; provided, however, that the Pre-Funded Warrants may not be exercised to the extent such exercise would cause the number of shares of the Issuer's Common Stock owned by the holder (together with its affiliates and certain other related parties) to exceed 9.99% of the total number of shares of the Issuer's Common Stock immediately after giving effect to such exercise, which percentage may be increased or decreased at the option of the holder upon 61 days' prior notice to the Issuer, not to exceed 19.99%.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Korro Bio (KRRO) report in this Form 4?
At what prices were Korro Bio (KRRO) securities acquired in the March 10, 2026 transactions?
Who is the direct beneficial owner of the Korro Bio (KRRO) securities in this Form 4?
What are the key terms of the Korro Bio (KRRO) Pre-Funded Warrants purchased?
AI-generated analysis. How Rhea-AI works. Not financial advice.